Taking the Long View: Medical Comorbidities that May Shift Treatment Decision-Making


Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine, Georgetown University School of Medicine, Washington, DC
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology

Dr. Kumar is the Chief of Infectious Diseases and Tropical Medicine at MedStar Georgetown University Hospital and Professor of Medicine in Microbiology at Georgetown University School of Medicine, where she also serves as the Senior Associate Dean of Students. She has served as both the Program Director and the Associate Program Director for the Infectious Diseases Fellowship.

She has won numerous awards and was the first woman to be inducted into the Golden Apple Orchard in 2004 for sustained teaching of medical students. She has also received awards for the teaching of residents including the Sol Katz Society Award for dedicated and sustained teaching of medical residents. In 2010, Dr. Kumar was inducted into the Magis Society of Master Teachers. Georgetown University School of Medicine also presented Dr. Kumar with the 2015 Founders’ Medal for Dedication and Leadership of Cura Personalis. In 2019 she received the Golden Apple Award for excellence in teaching medical students from the Class of 2019.

Dr. Kumar has also excelled in clinical research. She served as the Director of the Clinical Population Sciences Core for the DC CFAR (Washington, DC, Center for AIDS Research) until June 2020 and in this role worked tirelessly to decrease the incidence of new HIV infections within the District of Columbia. She is the Principal Investigator for the DC Cohort, which is a unique NIH-funded, city-wide longitudinal cohort for outpatients with HIV who receive care in Washington, D.C. She has more than 60 publications in peer reviewed journals.

Dr. Kumar’s public service includes serving as the Medical Director and volunteer at Gift of Peace, a Missionaries of Charity home that was founded by Mother Teresa and provides care to the uninsured and homeless in D.C. She also received a certificate of appreciation from the Peace Corps for her service in advising the Peace Corps on medical issues and the teaching she has provided to the Peace Corps Medical Officers.

Dr. Kumar was awarded the 2016 Mastership in the American College of Physicians. This honor was presented to her because of her integrity, positions of honor, eminence in practice and medical research, and her attainments in science, and in the art of medicine. In 2019, the Infectious Diseases Society of America (IDSA) Foundation named Dr. Kumar a Women of ID to recognize her profound impact on the field of infectious diseases and the lives of those around her. Considering the COVID-19 pandemic, Dr. Kumar serves as the Co-Chair for Medstar Health’s Response Team and is the Co-Chair for the COVID-19 Monoclonal Antibody Working Group.

Statement of Need

Hepatitis B virus (HBV) poses a significant burden, as it is associated with an increased risk of morbidity and mortality in conjunction with a reduced quality of life (QoL). It is imperative that clinicians take the long view when considering medical comorbidities that may shift treatment decision-making, including recognizing that patients with chronic hepatitis B (CHB) are at-risk for bone loss independent of their antiviral treatment and aligning treatment initiation and switching decisions to AASLD guideline recommendations in the presence of renal impairment and/or bone loss.

This CME Outfitters BriefCase introduces Khadi, a 58-year-old woman who recently immigrated to the United States from Ghana and presents to her primary care provider for a new patient examination. This case will show how to optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.

Learning Objectives

At the end of this CME/CE activity, participants should be able to optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.

The following learning objectives pertain only to those requesting CNE or CPE credit: Describe efficacy and safety profiles of current agents for treatment in patients with HBV.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-118-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kumar reports that she receives grants from Gilead Sciences, Inc.; GlaxoSmithKline; and Merck & Co, Inc. She is a consultant for Amgen Inc.; GlaxoSmithKline; and Merck & Co., Inc. She is a stock shareholder (directly purchased) of Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; and Pfizer Inc.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-118-H01-P.



Taking the Long View: Medical Comorbidities that May Shift Treatment Decision-Making
Event Date: 06/22/2021